Lynsey M. Drewett

Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends

J. Abraham, K. Pinilla, Lynsey M Drewett, 2022, Frontiers in Oncology.

The Lancet Breast Cancer Commission

O. Olopade, R. Jagsi, B. Zikmund‐Fisher, 2024, The Lancet.

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.

E. Provenzano, J. Abraham, H. Earl, 2022, Journal of Clinical Oncology.